CIS
CRSP icon

Capital International Sarl’s CRISPR Therapeutics CRSP Stock Holding History

Capital International Sarl’s Portfolio CRSP Stock Details CRSP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$5.52M Sell
101,238
-1,040
-1% -$54.8K 0.08% 153
2026
Q1 		$4.87M Buy
102,278
+7,509
+8% +$396K 0.08% 150
2025
Q4 		$4.97M Sell
94,769
-4,888
-5% -$293K 0.08% 153
2025
Q3 		$6.46M Buy
99,657
+8,140
+9% +$467K 0.11% 132
2025
Q2 		$4.45M Sell
91,517
-11,425
-11% -$442K 0.09% 152
2025
Q1 		$3.5M Sell
102,942
-83,978
-45% -$3.56M 0.08% 160
2024
Q4 		$7.36M Buy
186,920
+16,397
+10% +$774K 0.17% 117
2024
Q3 		$8.01M Buy
170,523
+21,130
+14% +$1.07M 0.21% 106
2024
Q2 		$8.07M Buy
149,393
+7,485
+5% +$433K 0.25% 97
2024
Q1 		$9.67M Buy
141,908
+39,234
+38% +$2.81M 0.32% 87
2023
Q4 		$6.43M Buy
102,674
+10,531
+11% +$582K 0.24% 102
2023
Q3 		$4.18M Buy
92,143
+6,708
+8% +$346K 0.19% 125
2023
Q2 		$4.8M Buy
85,435
+8,063
+10% +$458K 0.22% 124
2023
Q1 		$3.5M Buy
77,372
+18,855
+32% +$916K 0.18% 139
2022
Q4 		$2.38M Buy
58,517
+8,620
+17% +$457K 0.17% 145
2022
Q3 		$3.26M Buy
49,897
+18,618
+60% +$1.35M 0.26% 109
2022
Q2 		$1.9M Buy
31,279
+7,090
+29% +$417K 0.15% 150
2022
Q1 		$1.52M Buy
24,189
+4,027
+20% +$253K 0.08% 207
2021
Q4 		$1.53M Buy
20,162
+16,234
+413% +$1.42M 0.07% 204
2021
Q3 		$440K Sell
3,928
-274
-7% -$34.4K 0.04% 211
2021
Q2 		$680K Sell
4,202
-1,766
-30% -$215K 0.06% 192
2021
Q1 		$727K Sell
5,968
-4,175
-41% -$630K 0.07% 187
2020
Q4 		$1.55M Buy
10,143
+658
+7% +$77.8K 0.16% 127
2020
Q3 		$793K Buy
+9,485
New +$841K 0.1% 155

Other funds holding CRSP

AIM
ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
OAG
Orbis Allan Gray Hamilton, Bermuda $29.1B AUM 60.8% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
GP
GSK plc London $602M AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
SOCM
SR One Capital Management Wayne, Pennsylvania $1.04B AUM 262.99% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Capital International Sarl's CRSP Position: Q2 2026 in Review

Capital International Sarl reduced its CRISPR Therapeutics (CRSP) stake by 1% in Q2 2026, selling an estimated $54.8K and leaving 101,238 shares worth $5.52M. The position accounts for 0.08% of the portfolio, ranked #153.

Capital International Sarl first reported a position in CRSP in Q3 2020 and has held it in 24 quarters since. The position peaked at $9.67M in Q1 2024. 524 funds tracked by Wall St. Rank hold CRSP as of Q2 2026.

  • Capital International Sarl held 101,238 shares of CRISPR Therapeutics worth $5.52M as of Q2 2026.
  • Capital International Sarl sold 1,040 CRISPR Therapeutics shares in Q2 2026, an estimated $54.8K.
  • CRISPR Therapeutics made up 0.08% of Capital International Sarl's portfolio in Q2 2026, its #153 holding.
  • Capital International Sarl first reported a position in CRISPR Therapeutics in Q3 2020 and has held it in 24 quarters since.
  • Capital International Sarl's CRISPR Therapeutics position peaked at $9.67M in Q1 2024.
  • 524 funds tracked by Wall St. Rank held CRISPR Therapeutics as of Q2 2026.

Based on Capital International Sarl's 13F filing for Q2 2026, filed 12 Aug 2026.